Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient

David W. Denning; Daniel E. Stepan; Karl G. Blume; David A. Stevens

doi:10.1016/0163-4453(92)91066-K

Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient

David W. Denning, Daniel E. Stepan, Karl G. Blume, David A. Stevens^*

^*Corresponding author for this work

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Pulmonary aspergillosis following bone marrow transplantation carries a mortality of 94%, irrespective of current treatment. We treated a patient who had acquired aspergillosis some 80 days after allogencic bone marrow transplantation, with oral itraconazole, 600 mg daily. After initial deterioration, clinical and radiographic resolution occurred during 3 months of therapy despite severe graft-vs.-host and cytomegalovirus disease. Itraconazole should be considered for therapy of pulmonary aspergillosis in this and other immunocompromised settings.

Original language	English
Pages (from-to)	73-74,IN7-IN9,75-79
Journal	Journal Of Infection
Volume	24
Issue number	1
DOIs	https://doi.org/10.1016/0163-4453(92)91066-K
Publication status	Published - Jan 1992

Keywords

allogenic bone marrow transplantation
antibiotic prophylaxis
computer assisted tomography
immunosuppressive treatment
intravenous drug administration
lung aspergillosis
myelodysplastic syndrome

Access to Document

10.1016/0163-4453(92)91066-K

Cite this

@article{99d1d76c52194c34ae9f0fe7983169e0,

title = "Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient",

abstract = "Pulmonary aspergillosis following bone marrow transplantation carries a mortality of 94%, irrespective of current treatment. We treated a patient who had acquired aspergillosis some 80 days after allogencic bone marrow transplantation, with oral itraconazole, 600 mg daily. After initial deterioration, clinical and radiographic resolution occurred during 3 months of therapy despite severe graft-vs.-host and cytomegalovirus disease. Itraconazole should be considered for therapy of pulmonary aspergillosis in this and other immunocompromised settings.",

keywords = "allogenic bone marrow transplantation, antibiotic prophylaxis, computer assisted tomography, immunosuppressive treatment, intravenous drug administration, lung aspergillosis, myelodysplastic syndrome",

author = "Denning, {David W.} and Stepan, {Daniel E.} and Blume, {Karl G.} and Stevens, {David A.}",

year = "1992",

month = jan,

doi = "10.1016/0163-4453(92)91066-K",

language = "English",

volume = "24",

pages = "73--74,IN7--IN9,75--79",

journal = "Journal Of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders Co. Ltd",

number = "1",

}

TY - JOUR

T1 - Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient

AU - Denning, David W.

AU - Stepan, Daniel E.

AU - Blume, Karl G.

AU - Stevens, David A.

PY - 1992/1

Y1 - 1992/1

N2 - Pulmonary aspergillosis following bone marrow transplantation carries a mortality of 94%, irrespective of current treatment. We treated a patient who had acquired aspergillosis some 80 days after allogencic bone marrow transplantation, with oral itraconazole, 600 mg daily. After initial deterioration, clinical and radiographic resolution occurred during 3 months of therapy despite severe graft-vs.-host and cytomegalovirus disease. Itraconazole should be considered for therapy of pulmonary aspergillosis in this and other immunocompromised settings.

AB - Pulmonary aspergillosis following bone marrow transplantation carries a mortality of 94%, irrespective of current treatment. We treated a patient who had acquired aspergillosis some 80 days after allogencic bone marrow transplantation, with oral itraconazole, 600 mg daily. After initial deterioration, clinical and radiographic resolution occurred during 3 months of therapy despite severe graft-vs.-host and cytomegalovirus disease. Itraconazole should be considered for therapy of pulmonary aspergillosis in this and other immunocompromised settings.

KW - allogenic bone marrow transplantation

KW - antibiotic prophylaxis

KW - computer assisted tomography

KW - immunosuppressive treatment

KW - intravenous drug administration

KW - lung aspergillosis

KW - myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0026569455&partnerID=8YFLogxK

U2 - 10.1016/0163-4453(92)91066-K

DO - 10.1016/0163-4453(92)91066-K

M3 - Article

C2 - 1312563

AN - SCOPUS:0026569455

SN - 0163-4453

VL - 24

SP - 73-74,IN7-IN9,75-79

JO - Journal Of Infection

JF - Journal Of Infection

IS - 1

ER -

Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this